The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Drozdova E.A.

South-Ural State Medical University

Long-term outcomes of anti-VEGF therapy for macular edema in retinal vein occlusion

Authors:

Drozdova E.A.

More about the authors

Journal: Russian Annals of Ophthalmology. 2022;138(3): 140‑148

DOI: 10.17116/oftalma2022138031140

Read: 2562 times

Download PDF (RU)
Contact the author
Table of contents

LONG-TERM OUTCOMES OF ANTI-VEGF THERAPY FOR MACULAR EDEMA IN RETINAL VEIN OCCLUSION
LONG-TERM OUTCOMES OF ANTI-VEGF THERAPY FOR MACULAR EDEMA IN RETINAL VEIN OCCLUSION

To cite this article:

Drozdova EA. Long-term outcomes of anti-VEGF therapy for macular edema in retinal vein occlusion. Russian Annals of Ophthalmology. 2022;138(3):140‑148. (In Russ.)
https://doi.org/10.17116/oftalma2022138031140

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Analysis of the effe­ctiveness of cata­ract surgery in neovascular age-related macu­lar dege­neration. Russian Annals of Ophthalmology. 2024;(6):7-14
Dual inhi­bition of VEGF-A and angiopoietin-2 in the treatment of neovascular age-related macu­lar dege­neration and diabetic macu­lar edema. Russian Annals of Ophthalmology. 2024;(6):100-106
Biosimilars of rani­bizumab in reti­nal diseases: new possibilities in ophthalmology. Russian Annals of Ophthalmology. 2025;(2):106-116
Systemic bias in randomized clinical trials in different fields of medi­cine in 2014—2024: a narrative review. Russian Journal of Anesthesiology and Reanimatology. 2024;(6):79-88
Pharmacoepidemiological study of oxaliplatin safety (analysis of Russian spontaneous repo­rting data­base). Medi­cal Technologies. Asse­ssment and Choice. 2025;(1):76-83
The effe­ctiveness of combined chemotherapy and immu­notherapy, and the search for personalized approaches to treating adva­nced non-small cell lung cancer. P.A. Herzen Journal of Onco­logy. 2025;(4):37-45
Abstract:

Antiangiogenic therapy (anti-VEGF) is the standard in the treatment of many retinal vascular diseases, including macular edema associated with retinal vein occlusion (RVO). A large evidentiary basis has been collected, consisting of randomized clinical trials in which anti-VEGF therapy demonstrated a significant advantage over laser photocoagulation and placebo in patients with RVO. However, in everyday clinical practice the results are not always comparable to randomized clinical trials. This review presents an analysis of the current studies based on actual clinical practice. Their results helped identify the main aspects of antiangiogenic therapy that could improve the treatment outcomes for patients with RVO. Additionally, the article discusses the predictive factors for therapy outcomes and the effect of anti-VEGF therapy on the development of neovascular complications in patients with ischemic RVO.

Keywords:

anti-VEGF therapy
macular edema
retinal vein occlusion
real-life practice
aflibercept
ranibizumab

Authors:

Drozdova E.A.

South-Ural State Medical University

Received:

16.03.2022

Accepted:

21.04.2022

Close metadata

References:

  1. Song P, Xu Y, Zha M, Zhang Y, Rudan I. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health. 2019;9(1):010427. https://doi.org/10.7189/jogh.09.010427
  2. Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology. 2013;120(4):795-802.  https://doi.org/10.1016/j.ophtha.2012.09.032
  3. Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, et al. Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2019;242(3):123-162.  https://doi.org/10.1159/000502041
  4. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1124-1133.e1.  https://doi.org/10.1016/j.ophtha.2010.02.022
  5. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102-1112.e1.  https://doi.org/10.1016/j.ophtha.2010.02.021
  6. Heier JS, Clark WL, Boyer DS, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study [published correction appears in Ophthalmology. 2014;121(11):2293]. Ophthalmology. 2014;121(7):1414-1420.e1.  https://doi.org/10.1016/j.ophtha.2014.01.027
  7. Korobelnik JF, Holz FG, Roider J, et al. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. Ophthalmology. 2014;121(1): 202-208.  https://doi.org/10.1016/j.ophtha.2013.08.012
  8. Clark WL, Boyer DS, Heier JS, et al. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. Ophthalmology. 2016;123(2):330-336.  https://doi.org/10.1016/j.ophtha.2015.09.035
  9. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119(4):802-809.  https://doi.org/10.1016/j.ophtha.2011.12.005
  10. Campochiaro PA, Sophie R, Pearlman J, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014;121(1):209-219.  https://doi.org/10.1016/j.ophtha.2013.08.038
  11. Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16:495.  https://doi.org/10.1186/s13063-015-1023-4
  12. Spooner K, Fraser-Bell S, Hong T, Chang AA. Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors. BMJ Open Ophthalmol. 2019;4(1):e000249. https://doi.org/10.1136/bmjophth-2018-000249
  13. Pearce I, Clemens A, Brent MH, Lu L, Gallego-Pinazo R, Minnella AM, et al. Real world outcomes with ranibizumab in branch retinal vein occlusion: The prospective, global, LUMINOUS study. PLoS One. 2020;15(6): e0234739. https://doi.org/10.1371/journal.pone.0234739
  14. Pielen A, Clark WL, Boyer DS, et al. Integrated results from the COPERNICUS and GALILEO studies. Clin Ophthalmol. 2017;11:1533-1540. https://doi.org/10.2147/OPTH.S140665
  15. Thach AB, Yau L, Hoang C, Tuomi L. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials. Ophthalmology. 2014;121(5):1059-1066. https://doi.org/10.1016/j.ophtha.2013.11.022
  16. Liu Y, Shen J, Fortmann SD, Wang J, Vestweber D, Campochiaro PA. Reversible retinal vessel closure from VEGF-induced leukocyte plugging. JCI Insight. 2017;2(18):e95530. https://doi.org/10.1172/jci.insight.95530
  17. Hsueh J, Wai KM, Conti FF, Conti TF, Singh RP. Impact of Time to Anti-Vascular Endothelial Growth Factor Intervention on Visual Outcomes for Patients Diagnosed With Retinal Vein Occlusion. Ophthalmic Surg Lasers Imaging Retina. 2018;49(11):832-837.  https://doi.org/10.3928/23258160-20181101-03
  18. Ciulla T, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes. Br J Ophthalmol. 2021;105(12):1696-1704. Epub 2020 Oct 14.  https://doi.org/10.1136/bjophthalmol-2020-317337
  19. Lotery A, Clemens A, Tuli R, et al. Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study. Eye (Lond). 2021 Jul 29. Online ahead of print. https://doi.org/10.1038/s41433-021-01702-y
  20. Spooner KL, Fraser-Bell S, Hong T, Wong JG, Chang AA. Long-term outcomes of anti-VEGF treatment of retinal vein occlusion. Eye (Lond). 2021 Jun 11. Online ahead of print. https://doi.org/10.1038/s41433-021-01620-z
  21. Fayzrakhmanov RR. Anti-VEGF dosing regimen for neovascular age-related macular degeneration treatment. The Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2018;134(6):107-115. (In Russ.). https://doi.org/10.17116/oftalma2018134061107
  22. Lanzetta P, Loewenstein A; Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255(7):1259-1273. https://doi.org/10.1007/s00417-017-3647-4
  23. Iftikhar M, Mir TA, Hafiz G, et al. Loss of Peak Vision in Retinal Vein Occlusion Patients Treated for Macular Edema. Am J Ophthalmol. 2019;205:17-26.  https://doi.org/10.1016/j.ajo.2019.03.029
  24. Eleftheriadou M, Nicholson L, D’Alonzo G, Addison PKF. Real-Life Evidence for Using a Treat-and-Extend Injection Regime for Patients with Central Retinal Vein Occlusion. Ophthalmol Ther. 2019;8(2):289-296.  https://doi.org/10.1007/s40123-019-0184-8
  25. Yang KB, Liu L, Feng H, et al. Outcomes of Eyes Lost to Follow-Up in Patients with Central Retinal Vein Occlusion Who are Receiving Anti-Vascular Endothelial Growth Factor Treatment. Ther Clin Risk Manag. 2021;17: 489-496.  https://doi.org/10.2147/TCRM.S303248
  26. Tultseva SN, Astakhov YS, Nechiporenko PA, Ovnanyan AY, Khatina VA. Ranibizumab and retinal photocoagulation in the treatment of ischemic retinal vein occlusion. Ophthalmology Journal = Oftal’mologicheskiye vedomosti. 2015;8(2):11-27. (In Russ.). https://doi.org/10.17816/OV2015211-27
  27. Abri Aghdam K, Reznicek L, Soltan Sanjari M, Klingenstein A, Kernt M, Seidensticker F. Anti-VEGF treatment and peripheral retinal nonperfusion in patients with central retinal vein occlusion. Clin Ophthalmol. 2017;11:331-336.  https://doi.org/10.2147/OPTH.S125486
  28. de Salles MC, Epstein D. Real-life study of the use of anti-VEGF therapy versus dexamethasone implant for treatment of macular edema in retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2021;259(9):2653-2660. https://doi.org/10.1007/s00417-021-05146-8
  29. Chatziralli I, Theodossiadis G, Chatzirallis A, Parikakis E, Mitropoulos P, Theodossiadis P. RANIBIZUMAB FOR RETINAL VEIN OCCLUSION: Predictive Factors and Long-Term Outcomes in Real-Life Data. Retina. 2018;38(3):559-568.  https://doi.org/10.1097/IAE.0000000000001579
  30. State register of medicines. Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata Eylea LP-003544 ot 2020 g. (In Russ.). https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=9e73411f-469d-4c90-a305-0bb1ec0aefdc&t=
  31. State register of medicines. Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata Lucentis LSR-004567/08 ot 2021 g. (In Russ.). https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=3fd02ed3-e9fc-4835-97a4-56d19b69227c&t=
  32. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171-185.  https://doi.org/10.1007/s10456-011-9249-6
  33. Noma H, Mimura T, Yasuda K, Shimura M. Role of soluble vascular endothelial growth factor receptor signaling and other factors or cytokines in central retinal vein occlusion with macular edema. Invest Ophthalmol Vis Sci. 2015;56(2):1122-1128. https://doi.org/10.1167/iovs.14-15789
  34. Saishin Y, Ito Y, Fujikawa M, Sawada T, Ohji M. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion. Jpn J Ophthalmol. 2017;61(1):67-73.  https://doi.org/10.1007/s10384-016-0476-7
  35. Hunt AR, Nguyen V, Creuzot-Garcher CP, et al. Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry. Br J Ophthalmol. 2021;bjophthalmol-2020-318491. Online ahead of print. https://doi.org/10.1136/bjophthalmol-2020-318491
  36. Casselholm de Salles M, Amrén U, Kvanta A, Epstein DL. Injection frequency of aflibercept versus ranibizumab in a treat-and-extend regimen for central retinal vein occlusion: A Randomized Clinical Trial. Retina. 2019; 39(7):1370-1376. https://doi.org/10.1097/IAE.0000000000002171
  37. Spooner K, Fraser-Bell S, Hong T, Chang A. Patient-reported outcomes from a phase IV study of aflibercept in patients with refractory retinal vein occlusions. Taiwan J Ophthalmol. 2020;11(3):244-250.  https://doi.org/10.4103/tjo.tjo_19_20
  38. Noma H, Funatsu H, Yamasaki M, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005;140(2):256-261.  https://doi.org/10.1016/j.ajo.2005.03.003
  39. Shchuko AG, Zlobin IV, Yur’eva TN, Ostanin AA, Chernykh ER. Intraocular cytokines imbalance in retinal vein occlusion and its impact on the efficacy of anti-angiogenic therapy. The Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2015;131(2):50-58. (In Russ.). https://doi.org/10.17116/oftalma2015131250-58
  40. Drozdova EA, Khokhlova DYu, Mezentseva EA, Nikushkina KV. Studies of systemic and local cytokine level in retinal vein occlusion associated with antiangiogenic therapy. Medical Immunology (Russia) = Meditsinskaya immunologiya. 2018;20(3):365-372. (In Russ.). https://doi.org/10.15789/1563-0625-2018-3-365-372
  41. Noma H, Yasuda K, Shimura M. Cytokines and the Pathogenesis of Macular Edema in Branch Retinal Vein Occlusion. J Ophthalmol. 2019;2019: 5185128. https://doi.org/10.1155/2019/5185128
  42. Feltgen N, Hattenbach LO, Bertelmann T, et al. Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study. Acta Ophthalmol. 2018; 96(8):933-941.  https://doi.org/10.1111/aos.13770
  43. Bandello F, Augustin A, Tufail A, Leaback R. A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. Eur J Ophthalmol. 2018;28(6): 697-705.  https://doi.org/10.1177/1120672117750058
  44. Bandello F, Parravano M, Cavallero E, et al. Prospective evaluation of morphological and functional changes after repeated intravitreal dexamethasone implant (Ozurdex) for retinal vein occlusion. Ophthalmic Res. 2015;53(4): 207-216.  https://doi.org/10.1159/000381187
  45. Bezatis A, Spital G, Höhn F, et al. Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up — the SOLO study. Acta Ophthalmol. 2013;91(5):340-347.  https://doi.org/10.1111/aos.12020
  46. Bikbov MM, Fayzrakhmanov RR, Gil’manshin TR, Gilyazova II. Foveolar effects of dexamethasone intravitreal implant in central retinal vein occlusion. The Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2016; 132(2):21-25. (In Russ.). https://doi.org/10.17116/oftalma2016132221-25
  47. Budzinskaya MV, Shelankova AV, Nuriyeva NM. Evaluation of the effectiveness of intravitreal administration of a dexamethasone implant in patients with macular edema due to retinal vein occlusion. Sovremennye tekhnologii v oftal’mologii. 2020;1(32):298-302. (In Russ.). https://doi.org/10.25276/2312-4911-2020-2-298-302
  48. Gale R, Pikoula M, Lee AY, et al. Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser. Br J Ophthalmol. 2021;105(4):549-554.  https://doi.org/10.1136/bjophthalmol-2020-315836
  49. Jaissle GB, Szurman P, Feltgen N, et al. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2011;249(2): 183-192.  https://doi.org/10.1007/s00417-010-1470-2
  50. Zlobin IV, Zhukova SI, Shchuko AG, Iur’eva TN. Complex assessment of retinal ischemic damage in patients with retinal vein occlusion. The Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2019;135(2):62-69. (In Russ.). https://doi.org/10.17116/oftalma201913502162
  51. Light JG, Tian J, Wenick AS. Outcomes in Retinal Vein Occlusions Presenting with Poor Visual Acuity Treated with Anti-Vascular Endothelial Growth Factor Therapy: Prognosis and Predictive Factors. Ophthalmol Retina. 2021; 5(9):888-900.  https://doi.org/10.1016/j.oret.2020.11.010
  52. Brown DM, Wykoff CC, Wong TP, et al. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial. Retina. 2014;34(9):1728-1735. https://doi.org/10.1097/IAE.0000000000000191
  53. Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res. 2007;26(5):470-485.  https://doi.org/10.1016/j.preteyeres.2007.06.001
  54. Khokhlova DY, Drozdova EA, Kurysheva NI, Loskutov IA. Optical coherence tomographic patterns in patients with retinal vein occlusion and macular edema treated by ranibizumab: a predictive and personalized approach. EPMA J. 2021;12(1):57-66.  https://doi.org/10.1007/s13167-021-00233-6
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.